Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum + lactobacillus acidophilus + enterococcus faecalis (West China Hospital of Sichuan University)
- Development stage
- Unknown
- Lead developer
- Shanghai Xinyi Pharmaceutical Factory
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A probiotic combination drug consisting of live *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*. It is widely used in China under the brand name BIFICO (Peifeikang) to treat intestinal dysbiosis and associated conditions like diarrhea and constipation. The product works by replenishing beneficial gut flora, which in turn inhibits the growth of harmful bacteria, lowers intestinal pH through the production of organic acids, and supports the integrity of the intestinal barrier. In clinical research, such as the Phase 4 trial conducted by West China Hospital of Sichuan University, it is being evaluated for its ability to alleviate gastrointestinal symptom clusters and improve quality of life in patients undergoing colorectal cancer surgery.
- Brand names
- BIFICOPeifeikang
- Other names
- triple live bacteria probiotic tabletsBifidobacterium triple live bacteria tabletsBifidobacterium, Lactobacillus, and Enterococcus faecalis Triple Live Bacteria Tablets双歧杆菌三联活菌片
02
Targets
NLRP6 inflammasomeTLR4 (Toll-like receptor 4)TLR5TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on bifidobacterium longum + lactobacillus acidophilus + enterococcus faecalis (West China Hospital of Sichuan University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum + lactobacillus acidophilus + enterococcus faecalis (West China Hospital of Sichuan University).